Sepsis: pathophysiology and clinical management

Sepsis, severe sepsis, and septic shock represent increasingly severe systemic inflammatory responses to infection. Sepsis is common in the aging population, and it disproportionately affects patients with cancer and underlying immunosuppression. In its most severe form, sepsis causes multiple organ dysfunction that can produce a state of chronic critical illness characterized by severe immune dysfunction and catabolism. Much has been learnt about the pathogenesis of sepsis at the molecular, cell, and intact organ level. Despite uncertainties in hemodynamic management and several treatments that have failed in clinical trials, investigational therapies increasingly target sepsis induced organ and immune dysfunction. Outcomes in sepsis have greatly improved overall, probably because of an enhanced focus on early diagnosis and fluid resuscitation, the rapid delivery of effective antibiotics, and other improvements in supportive care for critically ill patients. These improvements include lung protective ventilation, more judicious use of blood products, and strategies to reduce nosocomial infections.

[1]  Lutz Hamann,et al.  Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock , 2009, Proceedings of the National Academy of Sciences.

[2]  M. Singer The role of mitochondrial dysfunction in sepsis-induced multi-organ failure , 2013, Virulence.

[3]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[4]  S. Brett,et al.  Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality , 2014, BMJ : British Medical Journal.

[5]  C. Hinds,et al.  Elevation of systemic oxygen delivery in the treatment of critically ill patients. , 1994, The New England journal of medicine.

[6]  Timing of Therapy in Sepsis: Are Early Antibiotics Important for Prognosis? , 2015, Critical care medicine.

[7]  I. Koh,et al.  MICROCIRCULATORY EVALUATION IN SEPSIS: A DIFFICULT TASK , 2010, Shock.

[8]  Henry E. Wang,et al.  Chronic Medical Conditions and Risk of Sepsis , 2012, PloS one.

[9]  Shizuo Akira,et al.  Autophagy in infection, inflammation and immunity , 2013, Nature Reviews Immunology.

[10]  R. Hotchkiss,et al.  Immunosuppression in patients who die of sepsis and multiple organ failure. , 2011, JAMA.

[11]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[12]  S. Lemeshow,et al.  Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients* , 2007, Critical care medicine.

[13]  D. Annane,et al.  The Neuropathology of Septic Shock , 2004, Brain pathology.

[14]  Stephen J. Huang,et al.  Genome-wide transcription profiling of human sepsis: a systematic review , 2010, Critical care.

[15]  M. Wichmann,et al.  Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome , 2000, Intensive Care Medicine.

[16]  J. Marshall,et al.  Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome , 2014, BMC Infectious Diseases.

[17]  OLAND,et al.  TREATMENT OF SEPTIC SHOCK WITH THE TUMOR NECROSIS FACTOR RECEPTOR : Fc FUSION PROTEIN C , 2000 .

[18]  T. van der Poll,et al.  Mesenchymal stem cells as a therapeutic tool to treat sepsis. , 2015, World journal of stem cells.

[19]  Timothy J. Brennan,et al.  Early physical and occupational therapy in mechanically ventilated , critically ill patients : A randomised controlled trial , 2009 .

[20]  K. Tracey Reflex control of immunity , 2009, Nature Reviews Immunology.

[21]  E. Vicaut,et al.  Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: A randomized controlled trial* , 2009, Critical care medicine.

[22]  J. Vincent,et al.  Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis* , 2003, Critical care medicine.

[23]  R. M. Pino,et al.  Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis , 2018 .

[24]  G. Bernard,et al.  Cigarette Smoke Exposure and the Acute Respiratory Distress Syndrome* , 2015, Critical care medicine.

[25]  H. Wolinsky Circulation Research an Official Journal of the American Heart Association a Proposal Linking Clearance of Circulating Lipoproteins to Tissue Metabolic Activity as a Basis for Understanding Atherogenesis , 2022 .

[26]  M. Antonelli,et al.  Albumin replacement in patients with severe sepsis or septic shock. , 2014, The New England journal of medicine.

[27]  B. Engelmann,et al.  Thrombosis as an intravascular effector of innate immunity , 2012, Nature Reviews Immunology.

[28]  G. Van den Berghe,et al.  Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit* , 2009, Critical care medicine.

[29]  J. Dorca,et al.  Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes , 2009, Thorax.

[30]  S. Opal,et al.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. , 2001, JAMA.

[31]  The Autodigestion Hypothesis for Shock and Multi-organ Failure , 2014, Annals of Biomedical Engineering.

[32]  T. Wienker,et al.  Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study , 2015, The Lancet. Respiratory medicine.

[33]  M. Netea,et al.  TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans , 2007, Proceedings of the National Academy of Sciences.

[34]  M. Revel,et al.  Comparison of two fluid-management strategies in acute lung injury, H.P. Wiedemann, A.P. Wheeler, G.R. Bernard, B.T. Thompson, D. Hayden, B. deBoisblanc, A.F Jr. Connors, R.D. Hite, A.L. Harabin, in: N Engl J Med, 354. (2006), 2564 , 2007 .

[35]  Simon Finfer,et al.  Sedation and delirium in the intensive care unit. , 2014, The New England journal of medicine.

[36]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[37]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[38]  E. Abraham,et al.  IMMUNOMODULATION AND SEPSIS: IMPACT OF THE PATHOGEN , 2004, Shock.

[39]  J. Tenhunen,et al.  Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. , 2012, The New England journal of medicine.

[40]  R. Bellomo,et al.  Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation. , 2015, Seminars in nephrology.

[41]  D. Chemla,et al.  Effects of norepinephrine on mean systemic pressure and venous return in human septic shock* , 2012, Critical care medicine.

[42]  T. van der Poll,et al.  The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. , 2006, Gastroenterology.

[43]  J. Sunderram,et al.  Occurrence and outcomes of sepsis: Influence of race* , 2007, Critical care medicine.

[44]  C. Doig,et al.  Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients. , 1998, American journal of respiratory and critical care medicine.

[45]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[46]  François Gouin,et al.  Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults: A Multicenter Prospective Study in Intensive Care Units , 1995 .

[47]  B. van Hout,et al.  Prevalence and incidence of severe sepsis in Dutch intensive care units , 2004, Critical care.

[48]  E. Mascha,et al.  Smoking and Perioperative Outcomes , 2011, Anesthesiology.

[49]  Heinz Redl,et al.  Abandon the Mouse Research Ship? Not Just Yet! , 2014, Shock.

[50]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[51]  M. Puskarich,et al.  The Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock: A Systematic Review and Meta-Analysis* , 2015, Critical care medicine.

[52]  K. Maitland,et al.  Mortality after fluid bolus in African children with severe infection. , 2011, The New England journal of medicine.

[53]  F. Ansaldi,et al.  Vaccine-preventable diseases: from paediatric to adult targets. , 2014, European journal of internal medicine.

[54]  J. Vincent,et al.  Evolving concepts in sepsis definitions. , 2011, Critical care nursing clinics of North America.

[55]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[56]  C. Natanson,et al.  Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly. , 2006, The New England journal of medicine.

[57]  Finding a needle in the haystack: leveraging bioinformatics to identify a functional genetic risk factor for sepsis death. , 2015, Critical care medicine.

[58]  D. Salgado,et al.  Coupling microcirculation to systemic hemodynamics , 2010, Current opinion in critical care.

[59]  K. Walley,et al.  Identification of a Nonsynonymous Polymorphism in the SVEP1 Gene Associated With Altered Clinical Outcomes in Septic Shock* , 2015, Critical care medicine.

[60]  F. Moore,et al.  POST‐INJURY MULTIPLE ORGAN FAILURE: THE ROLE OF THE GUT , 2001, Shock.

[61]  T. Rice,et al.  Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury: The EDEN Randomized Trial , 2012 .

[62]  R. Bellomo,et al.  Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. , 2012, American journal of respiratory and critical care medicine.

[63]  G. Zimmerman,et al.  The acute respiratory distress syndrome. , 2012, The Journal of clinical investigation.

[64]  Derek Wheeler,et al.  Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. , 2015, American journal of respiratory and critical care medicine.

[65]  D. Harrison,et al.  The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database , 2006, Critical care.

[66]  T. Lisboa,et al.  Critically ill patients with cancer and sepsis: clinical course and prognostic factors. , 2012, Journal of critical care.

[67]  I. Chaudry,et al.  Gender differences in sepsis , 2013, Virulence.

[68]  I. Androulakis,et al.  Temporal Metabolic Profiling of Plasma During Endotoxemia in Humans , 2013, Shock.

[69]  M. Singer,et al.  Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. , 2013, JAMA.

[70]  C. Werner,et al.  Impaired cerebrovascular autoregulation in patients with severe sepsis and sepsis-associated delirium , 2012, Critical Care.

[71]  E. Lang,et al.  Vasopressors for hypotensive shock. , 2013, Annals of emergency medicine.

[72]  M. Oosting,et al.  Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. , 2012, The Journal of infectious diseases.

[73]  Claude Guerin,et al.  High versus low blood-pressure target in patients with septic shock. , 2014, The New England journal of medicine.

[74]  Derek Bell,et al.  Trial of early, goal-directed resuscitation for septic shock. , 2015, The New England journal of medicine.

[75]  G. Van den Berghe,et al.  Early versus Late Parenteral Nutrition in Critically Ill Adults , 2011, The New England journal of medicine.

[76]  Jay Steingrub,et al.  International study of the prevalence and outcomes of infection in intensive care units , 2009 .

[77]  Kevin J. Tracey,et al.  Sepsis definitions: time for change , 2013, The Lancet.

[78]  D. Annane,et al.  Brain lesions in septic shock: a magnetic resonance imaging study , 2007, Intensive Care Medicine.

[79]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[80]  S. Baudouin,et al.  A systematic review of the quality of genetic association studies in human sepsis , 2006, Intensive Care Medicine.

[81]  Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality , 2014, BMJ : British Medical Journal.

[82]  J. Berger Brain lesions in septic shock: a magnetic resonance imaging study , 2008 .

[83]  S. Obaro,et al.  Fortnightly Review: The pneumococcal problem , 1996 .

[84]  J. Bernhagen,et al.  Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated View , 2013, Mediators of inflammation.

[85]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[86]  G. Bernard,et al.  Long-term cognitive impairment after critical illness. , 2014, The New England journal of medicine.

[87]  R. Hotchkiss,et al.  Reactivation of Multiple Viruses in Patients with Sepsis , 2014, PloS one.

[88]  K. Tracey,et al.  Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin , 2000, Nature.

[89]  D. Dunn Role of endotoxin and host cytokines in septic shock. , 1991, Chest.

[90]  J. Wetterslev,et al.  Vitamin D supplementation for prevention of mortality in adults. , 2014, The Cochrane database of systematic reviews.

[91]  R. Hotchkiss,et al.  Persistent Lymphopenia After Diagnosis of Sepsis Predicts Mortality , 2014, Shock.

[92]  John Land,et al.  Association between mitochondrial dysfunction and severity and outcome of septic shock , 2002, The Lancet.

[93]  Rajit K. Basu,et al.  Sepsis-associated acute kidney injury. , 2015, Seminars in nephrology.

[94]  J. Vincent,et al.  Impact of infection on the prognosis of critically ill cirrhotic patients: results from a large worldwide study , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[95]  J. Rello,et al.  Tobacco smoking increases the risk for death from pneumococcal pneumonia. , 2014, Chest.

[96]  Anand Kumar,et al.  Role of the Venous Return in Critical Illness and Shock: Part II—Shock and Mechanical Ventilation , 2013, Critical care medicine.

[97]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.

[98]  D. Berman,et al.  Right ventricular performance in septic shock: a combined radionuclide and hemodynamic study. , 1984, Journal of the American College of Cardiology.

[99]  M. Levi Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. , 2001, Journal of critical care.

[100]  A. Mebazaa,et al.  Septic shock: a heart story since the 1960s , 2006, Intensive Care Medicine.

[101]  J. Kress,et al.  Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. , 2000, The New England journal of medicine.

[102]  J. Ronco,et al.  Does increasing oxygen delivery improve outcome in the critically ill? No. , 1996, Critical care clinics.

[103]  R. Gamelli,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013, Proceedings of the National Academy of Sciences.

[104]  Gordon R Bernard,et al.  Comparison of two fluid-management strategies in acute lung injury. , 2006, The New England journal of medicine.

[105]  C. Clec’h,et al.  Influence of gender on the outcome of severe sepsis: a reappraisal. , 2007, Chest.

[106]  A. Avenell,et al.  Does Enteral Nutrition Affect Clinical Outcome? A Systematic Review of the Randomized Trials , 2007, The American Journal of Gastroenterology.

[107]  B. Levy,et al.  Lipid mediators in the resolution of inflammation. , 2015, Cold Spring Harbor perspectives in biology.

[108]  Michael Bailey,et al.  Goal-directed resuscitation for patients with early septic shock. , 2014, The New England journal of medicine.

[109]  Stephen E. Lapinsky,et al.  Interaction Between Fluids and Vasoactive Agents on Mortality in Septic Shock: A Multicenter, Observational Study* , 2014, Critical care medicine.

[110]  J. Shelhamer,et al.  Profound but reversible myocardial depression in patients with septic shock. , 1984, Annals of internal medicine.

[111]  Steven B. Johnson,et al.  Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* , 2004, Critical care medicine.

[112]  H. D. de Geus,et al.  Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis , 2014, Critical Care.

[113]  B. Souweine,et al.  Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile. , 2014, Chest.

[114]  J. Wetterslev,et al.  Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis , 2016, Intensive Care Medicine.

[115]  N. Benowitz,et al.  Active and passive cigarette smoking and acute lung injury after severe blunt trauma. , 2011, American journal of respiratory and critical care medicine.

[116]  P. Pronovost,et al.  An intervention to decrease catheter-related bloodstream infections in the ICU. , 2006, The New England journal of medicine.

[117]  M. Howell,et al.  Incidence and Prognostic Value of the Systemic Inflammatory Response Syndrome and Organ Dysfunctions in Ward Patients. , 2015, American journal of respiratory and critical care medicine.

[118]  C. Sprung,et al.  Definitions for sepsis and organ failure. , 1992, Critical care medicine.

[119]  M. Netea,et al.  Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. , 2006, European cytokine network.

[120]  Jesse B. Hall,et al.  Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial , 2009, The Lancet.

[121]  J. Vincent,et al.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.

[122]  D. Wagner,et al.  Thrombosis: tangled up in NETs. , 2014, Blood.

[123]  J. Marshall Why have clinical trials in sepsis failed? , 2014, Trends in molecular medicine.

[124]  P. T. Phang,et al.  Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. , 1993, JAMA.

[125]  R. Hotchkiss,et al.  Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. , 2013, American journal of respiratory and critical care medicine.

[126]  A. Muñoz,et al.  Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)* , 2009, Critical care medicine.

[127]  P. Asfar,et al.  Bench-to-bedside review: Circulating microparticles - a new player in sepsis? , 2010, Critical care.

[128]  W. Aird The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. , 2003, Blood.

[129]  D. Angus,et al.  Trends in the Epidemiology of Pediatric Severe Sepsis* , 2013, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[130]  M. Netea,et al.  Immunodeficiency and genetic defects of pattern-recognition receptors. , 2011, The New England journal of medicine.

[131]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[132]  Marc Moss,et al.  The effect of age on the development and outcome of adult sepsis* , 2006, Critical care medicine.

[133]  G Sherman,et al.  The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. , 1998, Chest.

[134]  S. Eiam‐Ong,et al.  Sepsis-Associated Acute Kidney Injury , 2019, Critical Care Pediatric Nephrology and Dialysis: A Practical Handbook.

[135]  Djillali Annane,et al.  Current epidemiology of septic shock: the CUB-Réa Network. , 2003, American journal of respiratory and critical care medicine.

[136]  D. Talan,et al.  Analysis of emergency department management of suspected bacterial meningitis. , 1989, Annals of emergency medicine.

[137]  G. Francis,et al.  The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. , 2015, American journal of respiratory and critical care medicine.

[138]  J. Vincent,et al.  Evolving concepts in sepsis definitions. , 2009, Critical care clinics.

[139]  M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive care medicine.

[140]  A. Maxwell,et al.  High-volume haemofiltration for sepsis. , 2013, The Cochrane database of systematic reviews.

[141]  K. Tracey,et al.  The "cytokine profile": a code for sepsis. , 2005, Trends in molecular medicine.

[142]  Theodore Speroff,et al.  Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. , 2004, JAMA.

[143]  Andrew Rhodes,et al.  Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.

[144]  F Doyon,et al.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. , 1995, JAMA.

[145]  R. Bellomo,et al.  Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial. , 2015, JAMA.

[146]  J. Vincent,et al.  Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels , 2014, BMC Infectious Diseases.

[147]  R. Bellomo,et al.  Pathophysiology of septic acute kidney injury: What do we really know? , 2008, Critical care medicine.

[148]  M. Levy,et al.  Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour: Results From a Guideline-Based Performance Improvement Program* , 2014, Critical care medicine.

[149]  T. Miyakawa,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .

[150]  M. Restrepo,et al.  Technologic advances in endotracheal tubes for prevention of ventilator-associated pneumonia. , 2012, Chest.

[151]  M. Levy,et al.  Promoting Global Research Excellence in Severe Sepsis (PROGRESS): Lessons from an International Sepsis Registry , 2009, Infection.

[152]  Kevin Delucchi,et al.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[153]  Craig R. Smith,et al.  Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial , 1995 .

[154]  V. Ranieri,et al.  The influence of gender on the epidemiology of and outcome from severe sepsis , 2013, Critical Care.

[155]  M. Fink Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness , 2003, Current opinion in critical care.

[156]  P. Pelosi,et al.  A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. , 1996, The New England journal of medicine.

[157]  V. Badovinac,et al.  Impact of sepsis on CD4 T cell immunity , 2014, Journal of leukocyte biology.

[158]  Jørn Wetterslev,et al.  Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis , 2007, BMJ : British Medical Journal.

[159]  R. Bellomo,et al.  Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. , 2014, JAMA.

[160]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[161]  J. Kress,et al.  Benzodiazepine Versus Nonbenzodiazepine-Based Sedation for Mechanically Ventilated, Critically Ill Adults: A Systematic Review and Meta-Analysis of Randomized Trials , 2013, Critical care medicine.

[162]  R. Munford Severe sepsis and septic shock: the role of gram-negative bacteremia. , 2006, Annual review of pathology.

[163]  D. Schoenfeld,et al.  Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. , 2001, American journal of respiratory and critical care medicine.

[164]  Michael Bailey,et al.  Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. , 2012, JAMA.

[165]  Shannon S Carson,et al.  Chronic critical illness. , 2010, American journal of respiratory and critical care medicine.

[166]  C. Deutschman,et al.  Sepsis: current dogma and new perspectives. , 2014, Immunity.

[167]  C. Brun-Buisson,et al.  EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units , 2004, Intensive Care Medicine.

[168]  T. van der Poll,et al.  Thrombomodulin in sepsis. , 2013, Minerva anestesiologica.

[169]  Arthur S Slutsky,et al.  Ventilator-induced lung injury. , 2013, The New England journal of medicine.

[170]  K. Tracey,et al.  Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. , 2002, Journal of vascular surgery.

[171]  J. Hallas,et al.  Risk Factors for Hospitalization Due to Community-Acquired Sepsis – A Population-Based Case-Control Study , 2015, PloS one.

[172]  Richard Beale,et al.  The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis* , 2010, Critical care medicine.

[173]  W. Schumer Steroids in the Treatment of Clinical Septic Shock , 1976, Annals of surgery.

[174]  Stephane Heritier,et al.  Intensive versus conventional glucose control in critically ill patients. , 2009, The New England journal of medicine.

[175]  Elie Azoulay,et al.  Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study* , 2011, Critical care medicine.

[176]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[177]  A. Anzueto,et al.  Predictors of Long-term Mortality After Severe Sepsis in the Elderly , 2014, The American journal of the medical sciences.

[178]  J. Vincent,et al.  Dopamine versus norepinephrine in the treatment of septic shock: A meta-analysis* , 2012, Critical care medicine.

[179]  J. A. Kruse,et al.  E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.

[180]  Jordi Rello,et al.  International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.

[181]  Joseph Johnston,et al.  Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care , 2004, Critical care.

[182]  Janet M Galiczewski Interventions for the prevention of catheter associated urinary tract infections in intensive care units: An integrative review. , 2016, Intensive & critical care nursing.

[183]  G. Patel,et al.  Systemic steroids in severe sepsis and septic shock. , 2012, American journal of respiratory and critical care medicine.

[184]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[185]  D. Gilroy,et al.  Pathways mediating resolution of inflammation: when enough is too much , 2013, The Journal of pathology.

[186]  B. Heniford,et al.  Risk factors for postoperative sepsis in laparoscopic gastric bypass , 2016, Surgical Endoscopy.

[187]  R. Stevens,et al.  Sepsis-associated encephalopathy and its differential diagnosis , 2010 .

[188]  V. Pettilä,et al.  Lower versus higher hemoglobin threshold for transfusion in septic shock. , 2014, The New England journal of medicine.

[189]  Mitchell M. Levy,et al.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.

[190]  F. Machado,et al.  Positive fluid balance as a prognostic factor for mortality and acute kidney injury in severe sepsis and septic shock. , 2015, Journal of critical care.

[191]  P. Barie,et al.  Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. , 2011, International journal of antimicrobial agents.

[192]  M. Krzyżaniak,et al.  Vagus nerve stimulation blocks vascular permeability following burn in both local and distal sites. , 2013, Burns : journal of the International Society for Burn Injuries.

[193]  Richard Beale,et al.  The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis , 2010, Intensive Care Medicine.

[194]  D. Levy-bruhl,et al.  Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction , 2013, Epidemiology and Infection.

[195]  M. Bauer,et al.  The late phase of sepsis is characterized by an increased microbiological burden and death rate , 2011, Critical care.

[196]  P. Pelosi,et al.  A Trial of Goal-Oriented Hemodynamic Therapy in Critically Ill Patients , 1995 .

[197]  S. Opal,et al.  High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .

[198]  C. Natanson,et al.  Antitumor Necrosis Factor Therapy Is Associated With Improved Survival in Clinical Sepsis Trials: A Meta-Analysis* , 2013, Critical care medicine.

[199]  M. Fink,et al.  Strategies to improve drug development for sepsis , 2014, Nature Reviews Drug Discovery.

[200]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[201]  Ian Needleman,et al.  Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. , 2016, The Cochrane database of systematic reviews.

[202]  J. Mira,et al.  Impact of case volume on survival of septic shock in patients with malignancies* , 2012, Critical care medicine.

[203]  N. Benowitz,et al.  Cigarette smoking and infection. , 2004, Archives of internal medicine.

[204]  Rita De Rosa,et al.  MOLECULAR IDENTIFICATION OF BLOODSTREAM PATHOGENS IN PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH SUSPECTED SEPSIS , 2010, Shock.

[205]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[206]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[207]  Larry A Nathanson,et al.  Serum lactate as a predictor of mortality in emergency department patients with infection. , 2005, Annals of emergency medicine.

[208]  K. Delucchi,et al.  Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome , 2014, Annals of Intensive Care.

[209]  D. Angus,et al.  Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis. , 2010, JAMA.

[210]  D. Schwartz,et al.  Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. , 2002, Archives of internal medicine.

[211]  J. Drazen Transparency for clinical trials--the TEST Act. , 2012, The New England journal of medicine.

[212]  P. Andersen,et al.  Genetic and environmental influences on premature death in adult adoptees. , 1988, The New England journal of medicine.

[213]  L. Moldawer,et al.  The future of murine sepsis and trauma research models , 2015, Journal of leukocyte biology.

[214]  R. Bellomo,et al.  Pathophysiology of septic acute kidney injury: a different view of tubular injury. , 2010, Contributions to nephrology.

[215]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[216]  P. Marik,et al.  Sepsis-associated hyperlactatemia , 2014, Critical Care.

[217]  Alan E. Jones,et al.  Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. , 2010, JAMA.

[218]  K. Jauch,et al.  Metabolic self-destruction in critically ill patients: origins, mechanisms and therapeutic principles. , 2014, Nutrition.

[219]  Amber E Barnato,et al.  A randomized trial of protocol-based care for early septic shock. , 2014, The New England journal of medicine.

[220]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[221]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[222]  R. Hotchkiss,et al.  Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans1 , 2001, The Journal of Immunology.

[223]  D. Angus,et al.  Racial variation in the incidence, care, and outcomes of severe sepsis: analysis of population, patient, and hospital characteristics. , 2008, American journal of respiratory and critical care medicine.

[224]  Charles N Serhan,et al.  Resolution of acute inflammation in the lung. , 2014, Annual review of physiology.

[225]  G. Bernard,et al.  Long-term cognitive impairment after critical illness. , 2013, The New England journal of medicine.

[226]  P. Ward,et al.  Sepsis, complement and the dysregulated inflammatory response , 2009, Journal of cellular and molecular medicine.

[227]  T. Lumley,et al.  Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. , 1999, JAMA.

[228]  S. Calvano,et al.  Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. , 2002, The Journal of infectious diseases.

[229]  Rahul Phadke,et al.  Acute skeletal muscle wasting in critical illness. , 2013, JAMA.

[230]  Edward Abraham,et al.  New Definitions for Sepsis and Septic Shock: Continuing Evolution but With Much Still to Be Done. , 2016, JAMA.

[231]  R. Balk,et al.  Evaluating the Adequacy of Fluid Resuscitation in Patients with Septic Shock: Controversies and Future Directions , 2012, Hospital practice.

[232]  W. Kuebler,et al.  Novel regulators of endothelial barrier function. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[233]  L. Zhao,et al.  Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. , 2008, The New England journal of medicine.

[234]  T. Baumann,et al.  Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. , 2009, American journal of respiratory and critical care medicine.